New & Noteworthy

Stamping on MAPPs: Is Europe Trapped Again by Division?

Just as the medicine adaptive pathways to patients (MAPPs) gains currency, the EU has introduced STAMP, which is intended to assist the process but might well suffocate it. Reflector reports.

Are Global Markets Free-riding on the United States?

"Global free-riding" is the perception that the U.S. is subsidizing drugs for the rest of the world due to its high drug prices compared to other countries in the world. Ed Schoonveld reports.

The End of Pharma Marketing — or a New Beginning?

Two commercial marketing experts discuss how this mission critical function must change to stay relevant in bringing new therapies to the patients who need them.

A Blueprint for Launch

William Looney breaks down the four steps to a successful drug launch, using Keryx Biopharmaceuticals’ model for Auryxia, its new treatment for chronic kidney disease.

Memes: How is Pharma Using Them?

The interesting dynamic of industry-targeted memes in social media is still a quiet treading ground for pharmas, writes Casey McDonald.

Europe

Stamping on MAPPs: Is Europe Trapped Again by Division?

Just as the medicine adaptive pathways to patients (MAPPs) gains currency, the EU has introduced STAMP, which is intended to assist the process but might well suffocate it. Reflector reports.

Slow Growth to 2020 for France's Pharma Market

The French pharmaceutical market is forecast to grow at a "tepid" CAGR of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, according to GlobalData.

Greece's Anti-Austerity Government Sets Out Pharma Plans

Pharma and healthcare are among the many areas being viewed with increasing attention inside and outside Greece, following the victory in the country’s elections of the radical left-wing, anti-austerity Syriza party.

Global

Ebola Vaccines, Treatments Ramp Up for Clinical Trials

Several vaccine candidates are moving into larger clinical trials, supported by government and industry efforts to address manufacturing and research challenges. Jill Wechsler reports.

VC Optimism to China: Leading Biologics Company Raises $100m C Round

2014 was a banner year for investment in biotech, and there is little sign of decline. With an unprecedented $100m Series C round of financing, Innovent has demonstrated this optimism extends as far as China.

Got Ideas? Go North!

The Canadian R&D industry, which boasts a rich history of drug innovation, celebrates a series of anniversaries.

Strategy

Pharma 2015: Industry in Flux

What's hot and what's not this year? Is pharma still a 21st century growth industry? See our 2015 Strategic Outlook.

Supply Chain Analytics: Pharma’s Next Big Bet

Examining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.

Sanofi’s Big Bet on Integrated Patient Care

Pharm Exec profiles Sanofi EVP Pascale Witz, tagged with the assignment to move a lumbering biopharma giant closer to the embrace of the patient perspective in healthcare.

PEspeaks

Trending: Shire's Valley of the Dolls

Thanks to Shire's star drug Vyvanse, if you don't know much about binge-eating disorder, you soon will, writes Marylyn Donahue.

More Guidance, Fewer Warnings on Drug Advertising

FDA officials have been busy rolling out advisories for pharma marketers, and there’s no let-up in sight, writes Jill Wechsler.

Manufacturers Weigh Strategies to Prevent Drug Shortages

Drug shortages are declining, but they’re still a serious concern for regulatory authorities, policy makers and biopharma manufacturers, writes Jill Wechsler.

Income and Depression: A Predictive Model for Clinical Trials Patient Dropout

Moe Alsumidaie looks at data collection methods and concepts that can result in predicting patients at risk of dropping out from a clinical trial.

Withdrawal of EU Investigation of the Patent Box: Good News for UK Innovators

The European Commission’s (EC) decision to withdraw its investigation into the UK Government's Patent Box scheme is positive news for British innovators, writes Michael Jaeger.

Regulatory

Manufacturers Weigh Strategies to Prevent Drug Shortages

Drug shortages are declining, but they’re still a serious concern for regulatory authorities, policy makers and biopharma manufacturers, writes Jill Wechsler.

We Need New Financial Models for Biomedical Innovation

The ongoing battle over drug reimbursement and pricing has raised questions about whether the pharmaceutical industry can continue to rely on high U.S. revenues to fund biopharmaceutical R&D, writes Jill Wechsler.

Obama's Mixed Message for Biopharma R&D

President Obama has unveiled his $215m “Precision Medicine Initiative” to support the future biomedical research, while calling for a reduction in exclusivity on brand biologics from 12 to 7 years and a curb on "evergreen” patents on certain biologics. Jill Wechsler reports.

Does the Adaptive Pathways Debate Go Far Enough?

While such discussions have advanced in Europe, two key omissions from the dialogue may limit any real changes.

Sales & Marketing

What's Wrong with the Annual Sales Kickoff: And How to Fix it

New ways for pharma to make sure its sales reps stay sharp amid a flood of new information and a more complex selling climate. By Duncan Lennox.

Digital's Place in the Pharma Marketing Mix

The rush to digital will continue at a fast clip, but marketers need to reacquaint themselves with their brands' audiences.

OTC Drug Advertising: Alfred Hitchcock Style

The legendary director's on-screen attitude to his TV show's sponsor, Bristol-Myers, caused some consternation—until the drugmaker saw the results.

Social Media and the In-House Counsel

What is and what should be keeping you up at night.